Skip To Main Content
G. Giannone on Muck Rack

G. Giannone

As seen in: Nature, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to G. Giannone’s profile

Articles by G. Giannone

A tumour-derived organoid biobank maps cancer gene dependencies

|
By R. Ansari, J. L. Davis, J. Doran, K. L. Evans, M. Fekry, C. M. Hall, C. Hardy, L. Holland, N. Joshi, K. May, J. R. Morris, S. Russ Price, K. W. Smith, F. Thomas, S. Walker, A. C. Freeman, G. Giannone, N. Grehan, E. A. Griffiths, S. L. Lee, E. Leung, A. Mirnezami, A. M. Redmond, K. D. Roberts, S. Roy, D. A. Sanders, P. Taniere, OCCAMS Consortium, J. D. Brenton, I. A. McNeish, A. Biankin, O. J. Sansom, T. J. Underwood, R. C. Fitzgerald, A. D. Beggs, M. J. Garnett, C. Herranz-Ors, S. G. Bhosle, A. E. Beck, J. G. R. Gilbert, G. Picco, J. Espejo Valle-Inclan, F. Muyas, S. Valentini, A. E. Andres, S. Barthorpe, G. Battarbee, C. M. Beaver, S. Brocklesby, J. Cantwell, C. A. Collins, H. G. Dimitrova, E. Efendi, T. A. Fowler, M. Garcia-Casado, J. A. T. Griffiths, R. Hamer, Z. Hewitson, E. Hitch, D. A. Jackson, A. Kavasakali, L. Letchford, H. B. Lightfoot, H. Lingala, I. Mali, T. Mironenko, C. Pacini, G. Robert-Tissot, H. A. Rogers, J. V. Smith, E. Souster, W. J. Spence, S. F. Vieira, G. Alfonsin, H. Bermingham, H. Coles, D. P. Ennis, C. Loreno, C. Millington, B. Nutzinger, K. Orzechowska, C. M. A. Pinna, M. Vias, K. Wanigasooriya, M. R. Stratton, L. M. Staudt, U. McDermott, I. Cortes-Ciriano, H. E. Francies
| Nature Verified
Abstract Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines1.
Open in Who Shared Issue with article?

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors

|
By Byers Lauren Averett, M. Bartoletti, L. Musacchio, G. Giannone
| Cancer Treatment Reviews Verified
Highlights • PARP inhibitors have opened the era of targeted therapy in ovarian cancer; • Major therapeutic improvements have been limited to the high grade serous subtype; • The panorama of possible clinically actionable targets in ovarian cancer is wider. • New druggable alterations and matched drugs are under investigation.
Open in Who Shared Issue with article?
Show More